Olutasidenib for acute myeloid leukemia and myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a new drug called olutasidenib for people with certain blood cancers (acute myeloid leukemia or myelodysplastic syndromes) that have a specific genetic change (IDH1 mutation). The drug may be used alone or with other treatments, depending on the type of blood cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be enrolled in the MyeloMATCH study and have a specific genetic change called IDH1 mutation.
- If you have acute myeloid leukemia (AML), you must be 60 or older, or be 18-59 and not able to receive intensive chemotherapy.
- If you have a higher-risk myelodysplastic syndrome (MDS), you must not have had prior treatment for it.
- If you have a lower-risk MDS, you must have anemia requiring blood transfusions or have low blood counts, and you must not have used certain prior treatments.
- You must be generally healthy enough to participate, with kidney and liver function within the required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.